Immune checkpoint inhibitors may increase risk of atherosclerotic cardiovascular disease
1. In patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors were associated with ...
Tag: immunology
KLKB1 gene editing therapy reduces kallikrein levels in hereditary angioedema
1. In this randomized controlled trial, gene-editing therapy targeting the kallikrein B1 gene (KLKB1) led to a significant reduction in ...
Monocyte-to-HDL ratio may be an indicator of poor endothelial dysfunction in diabetics
1. This cross-sectional study is the first to identify the monocyte-to-HDL ratio (MHR) as an indicator of poor endothelial dysfunction ...
Live viral vaccines safe for pediatric solid organ transplant recipients
1. This cohort study of pediatric solid organ transplant (SOT) patients found that the measles-mumps-rubella (MMR) and varicella-zoster virus (VZV) ...
HPV vaccination is safe and effective at 10-year follow-up
1. In a long-term follow-up study of an earlier randomized control trial, participants demonstrated sustained immunity 10 years after receiving ...
Gene therapy improves bilirubin levels in Crigler-Najjar syndrome
1. In this randomized controlled trial, a high dose of GNT0003 gene therapy was associated with decreased serum bilirubin and ...
Dupilumab reduces the number exacerbations in patients with COPD and type two inflammation
1. In this randomized controlled trial, dupilumab use was associated with significantly fewer chronic obstructive pulmonary disease (COPD) exacerbations among ...
Adults with mpox have relatively low JYNNEOS vaccination rates
1. In this case-control study, adults with mpox were less likely to have been partially or fully vaccinated with the ...
Buleviritide reduces viral load in patients with chronic hepatitis D
1. In this randomized controlled trial, 48 weeks of buleviritide treatment resulted in reduced hepatitis D ribonucleic acid (RNA) levels ...
Ruxolitinib improves symptoms in patients with disabling pansclerotic morphea
1. In this case series, ruxolitinib was associated with improved inflammatory markers in patients with disabling pansclerotic morphea (DPM). 2. ...